MyImmune

MyImmune develops AI for antibody discovery, response prediction, and biomarker development. Its AbSapien antibody discovery rests on the observation that therapeutic antibodies are raised in animals or on display platforms and then engineered to work in humans, whereas AbSapien retrieves antibodies already selected inside healthy people, before immunogenicity and developability liabilities are built in. It also predicts which patients will respond to which therapies in cancer and autoimmune diseases, and translates immune repertoire data into biomarkers for diagnostics and clinical endpoints.

Against antibodies raised in animals and engineered afterward, MyImmune's differentiation is retrieving antibodies already selected inside healthy people, and its AI maps epitope-specific antibody clusters with more than 95% purity. It targets biotech companies unlocking novel targets from human immunology, pharmaceutical groups de-risking clinical trials with AI patient stratification, and CROs building predictive companion diagnostics for oncology and infectious diseases.